Show simple item record

dc.contributor.authorFindling, Robert L.
dc.contributor.authorKafantaris, Vivian
dc.contributor.authorPavuluri, Mani
dc.contributor.authorMcNamara, Nora K.
dc.contributor.authorMcClellan, Jon
dc.contributor.authorFrazier, Jean A.
dc.contributor.authorSikich, Linmarie
dc.contributor.authorKowatch, Robert
dc.contributor.authorLingler, Jacqui
dc.contributor.authorFaber, Jon
dc.contributor.authorRowles, Brieana M.
dc.contributor.authorClemons, Traci E.
dc.contributor.authorTaylor-Zapata, Perdita
dc.date.accessioned2012-08-16T20:08:45Z
dc.date.available2012-08-16T20:08:45Z
dc.date.issued2011-06
dc.identifier.bibliographicCitationFindling, R. L., Kafantaris, V., Pavuluri, M., McNamara, N. K., McClellan, J., Frazier, J. A., Sikich, L., Kowatch, R., Lingler, J., Faber, J., Rowles, B. M., Clemons, T. E., & Taylor-Zapata, P. 2011. Dosing Strategies for Lithium Monotherapy in Children and Adolescents with Bipolar I Disorder. Journal of Child and Adolescent Psychopharmacology, 21(3): 195-205. DOI: 10.1089/cap.2010.0084en
dc.identifier.issn1044-5463
dc.identifier.otherDOI: 10.1089/cap.2010.0084
dc.identifier.urihttp://hdl.handle.net/10027/8503
dc.descriptionThis is a copy of an article published in the Journal of Child and Adolescent Psychopharmacology © 2011 [copyright Mary Ann Liebert, Inc.]; The Journal of Child and Adolescent Psychopharmacology is available online at: http://www.liebertonline.com. DOI: 10.1089/cap.2010.0084en
dc.description.abstractObjective: The primary goal of this exploratory study was to obtain data that could lead to evidence-based dosing strategies for lithium in children and adolescents suffering from bipolar I disorder. Methods: Outpatients aged 7–17 years meeting Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic criteria for bipolar I disorder (manic or mixed) were eligible for 8 weeks of open label treatment with lithium in one of three dosing arms. In Arm I, participants began treatment at a dose of 300 mg of lithium twice daily. The starting dose of lithium in Arms II and III was 300 mg thrice daily. Patients in Arms I and II could have their dose increased by 300 mg/day, depending on clinical response, at weekly visits. Patients in Arm III also had mid-week telephone interviews after which they could also have their dose of lithium increased by 300 mg per day. Youths weighing <30 kg were automatically assigned to ArmI, whereas youths weighing ≥30 kg were randomly assigned to ArmI, II, or III. Randomization was balanced by age (7–11 years, 12–17 years) and sex in approximately equal numbers. A priori response criteria were defined as a Clinical Global Impressions-Improvement scale score of ≤2 and a 50% decrease from baseline on the Young Mania Rating Scale. Results: Of the 61 youths [32 males (52.5%)] who received open-label lithium, 60 youths completed at least 1 week of treatment and returned for a postbaseline assessment. Most patients had a ≥50% improvement in Young Mania Rating Scale score, and more than half of the patients (58%) achieved response. Overall, lithium was well tolerated. All three treatment arms had similar effectiveness, side effect profiles, and tolerability of lithium. Conclusions: On the basis of these results, a dosing strategy in which pediatric patients begin lithium at a dose of 300 mg thrice daily (with an additional 300 mg increase during the first week), followed by 300 mg weekly increases until a priori stopping criteria are met, will be used in an upcoming randomized, placebo-controlled trial. treatment and returned for a postbaseline assessment. Most patients had a 50% improvement in Young Mania Rating Scale score, and more than half of the patients (58%) achieved response. Overall, lithium was well tolerated. All three treatment arms had similar effectiveness, side effect profiles, and tolerability of lithium. Conclusions: On the basis of these results, a dosing strategy in which pediatric patients begin lithium at a dose of 300 mg thrice daily (with an additional 300 mg increase during the first week), followed by 300 mg weekly increases until a priori stopping criteria are met, will be used in an upcoming randomized, placebo-controlled trial.en
dc.description.sponsorshipThis project has been funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN275200503406C.en
dc.language.isoen_USen
dc.publisherMary Ann Lieberten
dc.subjectbipolar I disorderen
dc.subjectlithium monotherapyen
dc.titleDosing Strategies for Lithium Monotherapy in Children and Adolescents with Bipolar I Disorderen
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record